These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 7505775)

  • 1. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer.
    Roach M; Marquez C; Yuo HS; Narayan P; Coleman L; Nseyo UO; Navvab Z; Carroll PR
    Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):33-7. PubMed ID: 7505775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Value of PSA and (pre- postoperative) Gleason in predicting the potential lymphatic involvement in patients with prostatic cancer].
    Gómez Veiga F; Díaz Bermúdez J; Alvarez Castelo L; Lorenzo Patiño MJ; Rodríguez Rivera J; Chantada Abal V; Vázquez Martul E; González Martín M
    Arch Esp Urol; 1997; 50(1):33-9. PubMed ID: 9182486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment prostate-specific antigen and Gleason score predict the risk of extracapsular extension and the risk of failure following radiotherapy in patients with clinically localized prostate cancer.
    Roach M; Chen A; Song J; Diaz A; Presti J; Carroll P
    Semin Urol Oncol; 2000 May; 18(2):108-14. PubMed ID: 10875450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis.
    Heidenreich A; Varga Z; Von Knobloch R
    J Urol; 2002 Apr; 167(4):1681-6. PubMed ID: 11912387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer.
    Cagiannos I; Karakiewicz P; Eastham JA; Ohori M; Rabbani F; Gerigk C; Reuter V; Graefen M; Hammerer PG; Erbersdobler A; Huland H; Kupelian P; Klein E; Quinn DI; Henshall SM; Grygiel JJ; Sutherland RL; Stricker PD; Morash CG; Scardino PT; Kattan MW
    J Urol; 2003 Nov; 170(5):1798-803. PubMed ID: 14532779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.
    Partin AW; Kattan MW; Subong EN; Walsh PC; Wojno KJ; Oesterling JE; Scardino PT; Pearson JD
    JAMA; 1997 May; 277(18):1445-51. PubMed ID: 9145716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer.
    Briganti A; Chun FK; Salonia A; Gallina A; Farina E; Da Pozzo LF; Rigatti P; Montorsi F; Karakiewicz PI
    BJU Int; 2006 Oct; 98(4):788-93. PubMed ID: 16796698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perineural invasion and seminal vesicle involvement predict pelvic lymph node metastasis in men with localized carcinoma of the prostate.
    Stone NN; Stock RG; Parikh D; Yeghiayan P; Unger P
    J Urol; 1998 Nov; 160(5):1722-6. PubMed ID: 9783940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective analysis of prostate-specific markers in pelvic lymph nodes of patients with high-risk prostate cancer.
    Ferrari AC; Stone NN; Eyler JN; Gao M; Mandeli J; Unger P; Gallagher RE; Stock R
    J Natl Cancer Inst; 1997 Oct; 89(20):1498-504. PubMed ID: 9337346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. External validation of the updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection.
    Gacci M; Schiavina R; Lanciotti M; Masieri L; Serni S; Vagnoni V; Abdollah F; Carini M; Martorana G; Montorsi F
    Urol Int; 2013; 90(3):277-82. PubMed ID: 23296120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer.
    Karam JA; Svatek RS; Karakiewicz PI; Gallina A; Roehrborn CG; Slawin KM; Shariat SF
    Clin Cancer Res; 2008 Mar; 14(5):1418-22. PubMed ID: 18316564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
    Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
    BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer.
    Naito S; Kuroiwa K; Kinukawa N; Goto K; Koga H; Ogawa O; Murai M; Shiraishi T;
    J Urol; 2008 Sep; 180(3):904-9; discussion 909-10. PubMed ID: 18635221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup.
    Palapattu GS; Allaf ME; Trock BJ; Epstein JI; Walsh PC
    J Urol; 2004 Nov; 172(5 Pt 1):1860-4. PubMed ID: 15540739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting pelvic lymph node involvement in current-era prostate cancer.
    Rahman S; Cosmatos H; Dave G; Williams S; Tome M
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):906-10. PubMed ID: 21300478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer.
    Blute ML; Bergstralh EJ; Partin AW; Walsh PC; Kattan MW; Scardino PT; Montie JE; Pearson JD; Slezak JM; Zincke H
    J Urol; 2000 Nov; 164(5):1591-5. PubMed ID: 11025711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of lymphatic spreading in prostatic cancer by prostate-specific antigen and Gleason's score.
    Wu TT; Chen KK; Huang JK; Lee YH; Chen MT; Chang LS
    Eur Urol; 1994; 26(3):202-6. PubMed ID: 7528661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.